Research programme: radiosensitising and radioprotecting compounds - Radiation Control Technologies

Drug Profile

Research programme: radiosensitising and radioprotecting compounds - Radiation Control Technologies

Alternative Names: RCT-1938

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Radiation Control Technologies
  • Class
  • Mechanism of Action Apoptosis inhibitors; CD47 antigen inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute radiation syndrome; Head and neck cancer; Radioprotection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer(Adjuvant therapy) in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Radioprotection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top